Provider file · corrected on-record pricing
Henry Meds: the corrected numbers — file and status
Latest first-party read (September 17, 2026), from the open dataset. Henry Meds (read September 17, 2026 at henrymeds.com): tirzepatide — $349/mo: $349 month-to-month, nothing billed beside it; dose policy not stated; labs not advertised; pharmacies described, none named; cancellation: cancel any time from the patient portal, by email or by phone. semaglutide — no rankable price printed on the page read (the GLP-1 program page prints 'starts at $179/month' across semaglutide, liraglutide and tirzepatide ('varies by treatment plan and dosing') without naming which medication, and the semaglutide page…). The file below records this site’s earlier, dated read; any figure it carries that the provider’s page no longer prints is kept as dated history and is not ranked. Dated pages, regenerated on every build: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
The 2026 correction that named this site’s method: widely-remembered “$149” pricing re-verified to $297/month semaglutide and $449/month tirzepatide month-to-month, with the advertised ~$197 lane requiring a ~$2,364 prepay flagged non-refundable in captured terms (taxonomy; how drift happens). Oral lanes $179–$249 as listed. Structure: month-to-month exit exists at the M2M price; exit risk concentrates in the prepay. Consumer-signal note: the company’s BBB profile showed an F rating when last checked — a datapoint to weigh, not a verdict. Figures dated 2026-08-17, on-record tier; full checkout audit queued. External: henrymeds.com.